<DOC>
	<DOCNO>NCT00983359</DOCNO>
	<brief_summary>RATIONALE : Stereotactic radiation therapy may able send x-ray directly tumor cause less damage normal tissue . PURPOSE : This phase II trial study well stereotactic radiation therapy work treat patient brain metastasis</brief_summary>
	<brief_title>Stereotactic Radiation Therapy Treating Patients With Brain Metastases</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine neurological death rate follow initiation conformal stereotactic radiotherapy patient 1-3 brain metastasis . Secondary - To determine overall survival rate 6 month . - To determine progression-free survival rate brain metastasis recurrence rate 6 month . - To determine time neurological death , time systemic death , Karnofsky decay time . - To determine frequency severity adverse event associate conformal stereotactic radiotherapy . OUTLINE : Patients undergo conformal stereotactic radiotherapy 5 day area include 3 mm around metastasis surgical cavity . Patients may receive additional radiotherapy symptomatic metastasis emerge different site . After completion study treatment , patient follow 1 2 month every 3 month thereafter .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Histologyconfirmed cancer 1 3 symptomatic brain metastasis image MRI/CT scan . Have cancer originate central nervous system ( CNS ) Karnofsky score least 60 Given write consent At least 18 year age Prior whole brain radiotherapy prior focal radiotherapy metastasis/es consider trial . Certain radiosensitive primary tumor small cell lung cancer , germ cell tumor , lymphoma , leukemia multiple myeloma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>tumor metastatic brain</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>